
News|Articles|December 1, 2012
Escitalopram reduces the risk of depression in patients with HCV treated with interferon alpha
Pre-emptive therapy with the selective serotonin reuptake inhibitor escitalopram in patients initiating interferon therapy for hepatitis C virus (HCV) without psychiatric risk factors reduced the risk of depression, according to a recent study published in the Annals of Internal Medicine.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What IRA drug prices will mean for PBMs, health plans and patients
2
Biosimilars in 2025: A year of firsts
3
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
4
FDA approves first postmenopausal libido treatment, Addyi
5






















































